美国食品药品监督管理局（FDA）已批准将Linzess（利那洛肽）的适用范围扩展至两岁及以上的儿童功能性便秘患者。
然而，该药物对于两岁以下患儿存在严重脱水风险，因此在此年龄段禁用。此外，对于已知或疑似存在机械性胃肠道梗阻的患者，Linzess同样为禁忌用药。
美国食品药品监督管理局（FDA）已批准将Linzess（利那洛肽）的适用范围扩展至两岁及以上的儿童功能性便秘患者。
然而，该药物对于两岁以下患儿存在严重脱水风险，因此在此年龄段禁用。此外，对于已知或疑似存在机械性胃肠道梗阻的患者，Linzess同样为禁忌用药。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.